Startseite News

News From the Food and Drug Administration

17-03-2021 12:24

March 16, 2021

cell-based gene therapy to treat adults with large B-cell lymphoma (LBCL) has received FDA approval. Lisocabtagene maraleucel, marketed as Breyanzi, is a chimeric antigen receptor T-cell (CAR-T) therapy indicated for patients who haven’t responded to or have relapsed after at least 2 other systemic treatments.

Read More in JAMA. 2021;325(11):1032. doi:10.1001/jama.2021.3004



Einen Kommentar schreiben

Sie müssen sich anmelden, um Kommentare hinzuzufügen.